报价延迟最少15分钟:2026/04/17 22:50 EDT
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
23.015 
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-23.04/-0.21
|
|
企业价值
111.37M
|
| 资产负债 |
|
每股账面净值
11.59
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
0
|
|
每股收益
--
|
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比较之报价最少15分钟延迟 (夜盘时段除外)
|
业务概览
|
|||
| Pelthos Therapeutics Inc is a biopharmaceutical company committed to commercializing safe and efficacious therapeutic products to help patients with unmet treatment burdens. The Company currently has three U.S. Food and Drug Administration(FDA) approved products in its commercial portfolio, in various stages of commercialization, including ZELSUVMITM, XEPI, and XEGLYZE. The company operates in two reporting segments: the sale, promotion, and commercialization of approved commercial products, the Commercial Operations segment, and research and development activities related to developing a novel and proprietary class of NaV blockers that target the body's peripheral nervous system; and supportive activities toexpand the NITRICIL nitric oxide-based technology. |
